Document Detail


Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty.
MedLine Citation:
PMID:  8774625     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lipid lowering therapies were employed to prevent restenosis following elective percutaneous transluminal coronary angioplasty (PTCA). The effect of probucol was compared to that of Pravastatin in 141 coronary atherosclerosis patients. Probucol (750 mg/day) was administered for at least 30 days prior to PTCA (34 patients, group P-1) or less than 14 days prior to PTCA (27 patients, group P-2). Pravastatin (10 mg/day) was administered for at least 30 days prior to PTCA (38 patients, group V-1) or less than 14 days prior to PTCA (42 patients, group V-2). In group P-1, the patient restenosis rate was 17.6% and lesion restenosis rate was 14%. These rates were significantly lower than those of group V-1, which were 44.7% and 40.4% respectively (p < 0.05). The respective values were 48.1% and 51.8% in group P-2 (p < 0.05, vs group P-1) and 35.7% and 34% (p < 0.05, vs group P-1) in group V-2. Probucol seems to work, not only by lowering cholesterol but also by its antioxidative properties when administered for a sufficient period prior to PTCA.
Authors:
Y J Lee; H Daida; H Yokoi; H Miyano; J Takaya; H Sakurai; H Mokuno; H Yamaguchi
Related Documents :
7982415 - Effect of magnesium on restenosis after percutaneous transluminal coronary angioplasty:...
21936735 - Six and 12 months' effects of individual joint protection education in people with rheu...
9874045 - Two- to three-year follow-up of patients with single-vessel coronary artery disease ran...
16373265 - Drug-eluting stents for the treatment of in-stent restenosis--'real world' double centr...
20634725 - The intermediate clinical outcome and its limitations of bryan cervical arthroplasty fo...
7995835 - Endothelial cell seeded dacron aortobifurcated grafts: platelet deposition and long-ter...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Japanese heart journal     Volume:  37     ISSN:  0021-4868     ISO Abbreviation:  Jpn Heart J     Publication Date:  1996 May 
Date Detail:
Created Date:  1996-10-03     Completed Date:  1996-10-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0401175     Medline TA:  Jpn Heart J     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  327-32     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Juntendo University, School of Medicine, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Transluminal, Percutaneous Coronary*
Anticholesteremic Agents / therapeutic use*
Coronary Artery Disease / prevention & control,  therapy*
Female
Humans
Male
Middle Aged
Pravastatin / therapeutic use
Probucol / therapeutic use*
Prospective Studies
Recurrence
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 23288-49-5/Probucol; 81093-37-0/Pravastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Significant characteristics of variant angina patients with associated syncope.
Next Document:  Assessment of left atrial pressure and volume changes during atrial systole with transesophageal pul...